Soledad Cortina
University of Illinois, USA
Posters-Accepted Abstracts: J Blood Disord Transfus
FcγRIIB has long been known to inhibit the activity of therapeutic mAb. In addition to inhibition of effector cells, we recently showed that FcγRIIB can also engage mAb at the tumor cell surface transmit inhibitory signals and elicit internalization, thereby reducing efficacy. Here we show that highly specific antagonistic hFcγRIIb mAb are able to overcome many of these resistance mechanisms and so warrant clinical investigation in combination with existing therapeutic mAb.
Email: M.S.Cragg@soton.ac.uk